Prokarium Stock

Prokarium is biopharmaceutical company leading the oncology field of microbial immunotherapy.

Sign up today and learn more about Prokarium Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Prokarium Stock

Prokarium is a biopharmaceutical company leading the oncology field of microbial immunotherapy The Company’s pipeline is designed to unlock a new generation of immuno-oncology therapeutics by re engineering evolution into a synthetic biology platform Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune driven, long lasting antitumor effects

Funding History

January 2012$8.0M
March 2013$400K
August 2015$377K
July 2016$2.0M
February 2018$10.0M
October 2019$4.6M
October 2020$21.0M
February 2023$30.0M

Management

Chairman

Thomas Eldered

CEO

Kristen Albright

Chief Scientific Officer

Livija Deban

Board Member

Ted Fjällman

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo